INTRODUCTION
Breast cancer is one of the major health problems facing Western societies. The UK has a particularly high incidence and death rate with 25 000 cases and nearly 16000 deaths per annum. The high relapse rate but variable natural history thereafter means that the disease also has by far the highest prevalence of cancer in the UK, estimated at around 110000 women at any given time.
METHODS
After more than 25 years of clinical trials we have learned that adjuvant therapy, either hormonal or chemotherapy, reduces the risk of death from breast cancer up to 10 years after primary treatment. However, we also know that the effect of such therapy is far from adequate with only between one in four and one in five patients appearing to benefit from treatment", Another area of development has been the more precise definition of prognosis at presentation. A lot of work has been conducted looking at various pathological and biological parameters predicting outcome. However, there is still no individual feature which matches the information available from simply obtaining and counting the number of pathologically involved lymph nodes in the axilla at the time of primary surgery. Based on this we have a very good definition of relapse rates and survival in relation to node number and, as a result, a series of survival curves may be plotted against nodal status/. No groups achieve better than 80% survival but the worst groups (particularly those with more than 10 involved lymph nodes) show completely inadequate survival « 50%) beyond 5 years.
For about 10 years we have had the capacity to experiment safely with high dose chemotherapy. It has long been recognized that many cytotoxic agents exert their effects on cell lines in vitro in a dose-dependent manner such that a sigmoid survival curve is seen with a variety of cell lines and xenografts. There is no effect from the lowest dose of chemotherapy but after this initial 'lag phase' a virtual log-linear dose relationship obtains until at the very highest doses a plateau phase is reached by which time the drugs are also inducing lethal toxicity in the host 3 -5 . The classical drugs showing a true log-linear cancer cell kill against murine leukaemia and human breast xenografts and cell lines are the alkylating agents. They also produce most of their lethal host damage directly due to myelotoxicityf-", Marrow rescue or protection is thus the prerequisite for clinical dose-intensification research. Since the pragmatic experiments with autologous bone marrow rescue at the beginning of the 1980s the area of dose intensification research in the clinic become much more widely practised particularly for the haematological malignancies. Since then we have collectively learned lessons about lethal complications including 'second organ' toxicity.
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With increasing confidence in controlling complications of therapy, clinicians are now beginning to discover the potential benefits for this sort of approach in relatively chemosensitive solid cancers including breast cancer.
The overview analysis of adjuvant therapy of breast cancer points to benefit from both endocrine and chemotherapy. There is still a debate as to whether chemotherapy exerts its benefit for the premenopausal patients through secondary ovarian suppression but only one trial has ever directly addressed this question. The Scottish Group combined with Guy's Hospital tested ovarian ablation against chemotherapy and the overall results published in the Lancet in 1993 suggested an equivalent effect with no discernible overall benefit for one or the other treatment''. However, interestingly a subgroup analysis according to oestrogen receptor status fitted the hypothesis exactly that patients with oestrogen receptor positive tumours gained more from ovarian suppression whereas those with oestrogen receptor negative tumours gained benefit from chemotherapy. This suggests that biologically separate subgroups require tailored adjuvant therapy.
At present evidence for a dose response in breast cancer from clinical research is difficult to evaluate and is an area of great controversy. Influential retrospective studies on the relationship between dose intensity and outcome in breast cancer were conducted by Hryniuk and colleagues in the middle 1980s and certainly provided an impetus to further research in breast cancer both within the standard dose range and more recently in dose intensification's 10. Thus Hryniuk claimed that in advanced breast cancer there is a clear relationship between dose intensity and response rate, particularly complete response rate using a measure of dose of cytotoxic drug per unit time. When he examined the impact of this analysis in adjuvant trials of chemotherapy he showed quite a clear relationship between relapse-free survival and dose intensity. One of the problems with this analysis has been the lack of information on actual dose given as compared to intended doses. However, Bonadonna's analysis of his own trials in Italy seemed to indicate at least a threshold effect if not a true linear dose effect for delivered CMF dose and outcome!', Another argument against these interpretations is that equal weight was given to the dose-effect of a variety of different classes of cytotoxic agent including antimetabolites whereas the in vitro evidence of dose response is far less persuasive than that obtaining for alkylating agents. Nevertheless, a series of randomized clinical trials have been conducted in advanced disease and are ongoing in adjuvant therapy to test the hypothesis of dose intensity within the standard range 12-15. To date the results have been somewhat conflicting with the null hypothesis either being sustained or in some cases seeming to indicate a dose response effect. No studies have shown a reverse trend, which for the optimist suggests that there really is benefit from dose intensification even within the standard range of dose.
DISCUSSION
Whilst these experiments have been conducted in a number of centres, enthusiasts for dose intensification have attempted to examine much higher dose intensification using alkylating agents either alone or more frequently in combination. The argument in favour of combination dose intensification is quite strong based on laboratory studies and on the hypothesis of Goldie and Coleman which, briefly stated, indicates a level of spontaneous mutation in a cancer cell population of the order of one per 10 6 to one per 10 7 cells!", Arguing for non-cross resistant combination therapy.
In the laboratory, there is good evidence for drug limited cross resistance between alkylating agents using human cell lines. The current paradigm for anything more advanced than very small, node-negative breast cancer, is that micrometastatic disease is likely to be present, undetectable by conventional technology. Protagonists for dose intensification argue that it is in this clinical adjuvant setting that we have the best reflection of the laboratory model of a relatively small population of cancer cells in proliferative phase, amenable to access by cytotoxic drugs and resulting in the potential for a log linear kill for the putative micrometastatic disease. The evidence in favour of micrometastases being a common problem in 'localized' breast cancer is overwhelming and is substantiated by the ongoing studies of immuno-microdetection with antiepithelial monoclonal antibodies and by some investigators ability to culture tumour cells from bone marrow l7 ,!8. These studies indicate an increasing level of risk of marrow involvement as the risk factors rise in relation to the primary tumour. Current studies indicate that between 30-50% of bone marrows may have detectable disease depending on the clinical stage of the tumour at presentation.
Initial experiments with dose intensification therapy were conducted in a phase IIII 2esign in patients with refractory advanced disease then moved on to chemosensitive advanced disease and then from the middle 1980s experiments began within high risk groups for adjuvant therapy12.
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To date no randomized trials have been completed which give the answer as to whether dose intensification therapy produces benefits or not in adjuvant setting. However, randomized trials have now been commenced on the background of encouraging outcomes from phase II trials in which the outcomes have been compared against historical controls. Thus, the data from Duke University and from Milan both indicate very high relapse-free survival rates at 3 and 5 years which are clearly superior to those of 'matched' controls I9 ,20. However, these have not been substantiated yet. Prospective randomized trials therefore require to be performed. The outcomes for high risk breast cancer in terms of survival from systemic therapy with standard dose of chemotherapy are simply too poor not to test such promising approaches. The safety factors involved have changed the applicability of high dose therapy such that whereas 10 years ago up to 25% of patients were dying from complications of dose intensification, the figures are now well under 5% and possibly under 3%21,22. The result is that at least four European trials have commenced or are about to commence testing dose intensification and one very large trial, which is further ahead, in North America. Within the next 3-5 years we will begin to get clear indications as to whether there is clinical benefit from this approach.
